Abstract:Summary Background Influenza A (H3N2) virus (A/H3N2) has complex antigenic evolution, resulting in frequent vaccine strain updates. We aimed to evaluate the protective effect of the vaccine strains on the circulating strains from past ten years and provide a basis for finding a broader and more efficient A/H3N2 vaccine strain. Methods Eighty-four representative circulating A/H3N2 strains were selected from 65,791 deposited sequences in 2011–2020 and pseudotyped viruses were constructed with the VSV vector. We immunized guinea pigs with DNA vaccine containing the A/H3N2 components of the vaccine strains from 2011 to 2021 and tested neutralizing antibody against the pseudotyped viruses. We used a hierarchical clustering method to classify the eighty-four representative strains into different antigenic clusters. We also immunized animals with monovalent vaccine stock of the vaccine strains for the 2020–2021 and 2021–2022 seasons and tested neutralizing antibody against the pseudotyped viruses. Findings The vaccine strains PE/09, VI/11 and TE/12 induced higher levels of neutralizing antibody against representative strains circulating in recommended year and the year immediately prior whereas vaccine strains HK/14, HK/19 and CA/20 induced poor neutralization against all representative strains. The representative strains were divided into five antigenic clusters (AgV), which were not identical to gene clades. The AgV5 strains were most difficult to be protected among the five clusters. Compared with single-dose immunization, three doses of monovalent vaccine stock (HK/19 or CA/20) could induce stronger and broader neutralizing antibodies against strains in each of the antigenic clusters. Interpretation The protective effect of vaccine strains indicated that the accurate selection of A/H3N2 vaccine strains must remain a top priority. By increasing the frequency of immunization, stronger and broader neutralizing antibodies against strains in all antigenic clusters were induced, which provides direction for a new immunization strategy. Funding This work was supported by a grant from National Key R&D Program of China (No. 2021YFC2301700).

Establishment of seasonal influenza vaccine strain development platform

Molecular Characterization of A Novel Reassortant H1n2 Influenza Virus Containing Genes from the 2009 Pandemic Human H1n1 Virus in Swine from Eastern China

Preparation of Maternal Strain X-157 HA Antiserum for Influenza Virus

Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method

[Preparation and Identification of High Immunogenic A/PR/8/34 Maternal Strain HA Protein for Influenza Virus Classical Reassortment].

Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains

Construction and Comparison of Different Source Neuraminidase Candidate Vaccine Strains for Human Infection with Eurasian Avian-Like Influenza H1N1 Virus.

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Preclinical Evaluation of the Safety and Pathogenicity of a Live Attenuated Recombinant Influenza A/H7N9 Seed Strain and Corresponding MF59-adjuvanted Split Vaccine

Retrospective immunogenicity analysis of seasonal flu H3N2 vaccines recommended in the past ten years using immunized animal sera

Isolation and characterization of novel reassortant H6N1 avian influenza viruses from chickens in Eastern China

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Construction of a Chimeric Classical Swine Fever Virus C-strain Containing E2 of Group Ⅱ Isolate Remains and Its Biological Characteristics

Generation of a cold-adapted reassortant influenza A virus from cDNA and research on its immunogenicity

Development of a Universal Influenza Vaccine Based on NP and M1 Proteins of Influenza Virus

DEVELOPMENT OF A HIGH-GROWTH H9N2 REASSORTANT INFLUENZA VIRUS BY REVERSE GENETIC MANIPULATION ON CELLS

Generation of cold-adapted, attenuated reassortant human influenza A virus with eight-plasmid system

A Vero-cell-adapted Vaccine Donor Strain of Influenza A Virus Generated by Serial Passages.

Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform

Virological characterization of influenza A(H3N2) virus in Mainland China during 2011-2012]

Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness